Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant immunotherapy combinations in cisplatin-ineligible muscle-invasive bladder cancer
NCT04586244Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of retifanlimab in urothelial carcinoma (UC), sponsored by Incyte. Started Jan 2022; status: terminated.
02
Drugs
retifanlimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04586244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586244.